CN104800291B

CN104800291B - Magnolia officinalis extract and preparation method and application thereof

Info

Publication number: CN104800291B
Application number: CN201410034773.1A
Authority: CN
Inventors: 吴守方; 钟玉山; 卢昭岑
Original assignee: Development Center for Biotechnology
Current assignee: Development Center for Biotechnology
Priority date: 2014-01-24
Filing date: 2014-01-24
Publication date: 2020-07-03
Anticipated expiration: 2034-01-24
Also published as: CN104800291A

Abstract

The invention relates to a magnolia officinalis extract, a preparation method and application thereof, wherein the magnolia officinalis extract contains index active ingredients such as magnolia officinalis lignan C, magnolia officinalis lignan A, syringaresinol, cryptomerin and taiwan xylol, but does not contain magnolol and honokiol. The cortex Magnolia officinalis extract can be used to prepare medicinal products or health products for preventing or treating periodontal diseases.

Description

Magnolia officinalis extract and preparation method and application thereof

[ technical field ] A method for producing a semiconductor device

The present invention relates to a plant extract, a preparation method and a use thereof, and more particularly, to a mass production method for preparing a plant active extract by using a chromatographic separation principle in combination with a specific treatment method.

[ Prior Art ] A method for producing a semiconductor device

Periodontal disease is also called periodontitis, which is a disease of periodontal tissue, and is a chronic inflammation invading tissues such as gingiva, periodontal ligament and alveolar bone. Common chronic periodontal diseases can be generally classified into gingivitis and periodontitis, and these two diseases with different clinical symptoms are generally collectively called periodontal disease. Periodontal disease is a destructive disease caused by inflammation of periodontal tissues by toxins secreted from a periodontal bacterial membrane accumulated at the gingival margin, and is mainly characterized by formation of periodontal pockets and inflammation of pocket walls, alveolar bone resorption, and gradual loosening of teeth.

The cortex Magnolia officinalis is dry bark, branch bark or root bark of Magnolia officinalis (Magnolia officinalis) or Magnolia officinalis (Magnolia bioba) of Magnoliaceae, and is semi-circular and light brown. Magnolia officinalis is a traditional Chinese medicine, has warm nature and bitter and pungent taste, enters spleen, stomach, lung and large intestine channels, has the functions of eliminating dampness and dissolving phlegm, descending qi and relieving fullness, and is mainly used for treating damp stagnation in middle-jiao, epigastric fullness, vomiting and diarrhea, abdominal distention and constipation, phlegm retention, asthma and cough. Cortex Magnolia officinalis can be combined with radix aucklandiae, Zingiberis rhizoma, semen Alpiniae Katsumadai, pericarpium Citri Tangerinae, Poria, rhizoma Pinelliae, and herba Agastaches. For severe damp pathogen (chest distress, poor appetite, white, thick and greasy tongue coating, soft, smooth and slow pulse), rhizoma Atractylodis Macrocephalae, parched semen Coicis and fructus Amomi shell can be added. For instance, it is combined with Zhi Shi, Sheng Da Huang and Mang Xiao Cheng Qi Tang in Shang Han Lun (Hou Po, Zhi Shi, Sheng Da Huang and Mang Xiao), etc., for the syndrome of cold pathogen transforming into heat and heat accumulating in the intestines and stomach manifested as abdominal distention, stuffiness and fullness, constipation, fever in afternoon, delirium, etc. For the syndrome of fullness in chest and abdomen and dyspnea and cough due to adverse rising of qi, it is often combined with the syndrome of qi-descending, for example, Guizhi plus Houpo apricot kernel decoction (Guizhi, Baishao, Zhi Cao, Sheng Jiang, Zi Zao, Hou Po and xing ren) can be used for cough and dyspnea caused by external wind-cold and spontaneous perspiration; su Zi Jiang Qi Tang (Perilla seed, pinellia Tuber, roasted grass, Peucedanum praeruptorum, Magnolia officinalis, dried orange peel, Angelica sinensis, ginger, and Cinnamomum cassia) can be used for treating excessive phlegm, adverse qi, fullness in chest, cough and asthma. The magnolia officinalis has been discovered at present to have the drug effects of resisting virus, tumor, bacteria and ulcer, relieving pain, resisting inflammation, resisting oxidation and inhibiting autonomic nerve activity, wherein the main active ingredients are magnolol (magnolol) and honokiol (honokinol).

[ summary of the invention ]

The invention relates to a magnolia officinalis extract and a preparation method and application thereof; more particularly, the method relates to a method for preparing a plant active extract by matching a chromatographic separation principle with a specific treatment mode, which comprises the steps of boiling and extracting dried magnolia officinalis in water, adsorbing the water extract by macroporous adsorption resin, and then respectively stirring and separating by water and ethanol mixed solutions with different proportions to finally obtain the magnolia officinalis active extract, wherein the yield is 0.4%. Cell tests prove that the active extract has the effects of resisting bacteria and inflammation, and ligation-induced periodontal disease animal tests also prove that the active extract can effectively inhibit alveolar bone loss. Chemical composition analysis was confirmed by HPLC fingerprinting. The active extract produced by the process does not contain known components of magnolol and honokiol in the past, but contains other components such as magnolia bark lignan C (magnolignan C), magnolia bark lignan A (magnolignan A), syringin (syringaresinol), cryptomeridiol (cryptomeridiol), taiwan chayol (randaiol) and the like, and has the efficacy of effectively inhibiting oral bacteria, inflammation and alveolar bone loss.

Unless defined otherwise herein, scientific and technical terms used herein shall have the meanings that are commonly understood by those of skill in the art. The meaning and scope of these terms should be clear; however, in the case of any potential ambiguity, the definitions provided herein are superior to any dictionary or extrinsic definitions.

Unless otherwise indicated, the following terms, as used in this disclosure, are to be understood to have the following meanings.

The term "macroporous adsorbent resin" or "macroporous resin" (used interchangeably with each other) as used herein means an adsorbent resin prepared by polymerizing a polymeric monomer and additives such as a cross-linking agent, a porogen, a dispersant, etc. The macroporous adsorbent resin has high porosity inside in a dry state, and the pore diameter is large and is between about 50nm and 2000 nm. An example of a macroporous adsorbent resin is (including but not limited to) diaion hp20 resin.

The term "macroporous adsorbent resin column" as used herein means a chromatography column that utilizes primarily "macroporous adsorbent resin" or "macroporous resin", such as (including but not limited to)

HP-10、

HP-20、

HP-30、

HP-40、

HP-50、

XAD-4、

XAD-6、

XAD-7、

XAD-16、

XAD-1180 or

XAD-1600。

The term "extract" as used herein means a product obtained by extraction with respect to a substance, typically a solution or concentrated preparation obtained by soaking or mixing a substance to be extracted in a solvent. Typically, the extract is prepared from fresh plants or ground or dried plant samples. Various extraction methods are known in the art including, but not limited to, maceration, percolation, refiltering, digestion, counter current extraction, turbine extraction, extrusion/pressing/squeezing or supercritical fluid carbon dioxide extraction. Suitable solvents include, but are not limited to, water, ethanol/water mixtures, methanol, butanol, n-butanol, isobutanol, acetone, hexane, n-hexane, petroleum ether, ethyl acetate, dichloromethane, chloroform or other solvents. The solvent type or concentration can be selected as required to achieve suitable polarity for extraction, for example, low polarity solvents include but are not limited to petroleum ether, n-hexane, dichloromethane, chloroform, ethyl acetate, acetone, 70-100% ethanol; highly polar solvents include, but are not limited to, water, 50% or less ethanol, methanol, butanol, isobutanol, 80% or less acetone. The ratio of the material to be extracted to the solvent may be from about 1:1 to about 1:100(w/v (g/ml)), preferably from about 1:1 to about 1:50(w/v (g/ml)), more preferably from about 1:1 to about 1:20(w/v (g/ml)), even more preferably about 1:15 or 1:10(w/v (g/ml)). The extraction may be carried out at a suitable temperature, for example, at about 5 ℃ to about 100 ℃, about 10 ℃ to about 100 ℃, about 20 ℃ to about 100 ℃, about 40 ℃ to about 100 ℃, about 60 ℃ to about 100 ℃, preferably at room temperature of 25 ℃ or boiling at 100 ℃. The extracts of the different stages can be combined with each other or can be subjected to subsequent concentration steps, such as evaporation, or purification or separation steps, such as filtration, centrifugation and chromatography. In one example, all or part of a fresh plant or dried plant sample (chopped or ground as necessary) is mixed or soaked with an appropriate solvent and stirred for a sufficient period of time, such as 4 hours or more, 6 hours or more, 8 hours or more, 10 hours or more, 12 hours or more, 14 hours or more, or 16 hours or more, at room temperature or with heating, the solid residue (filter residue) is removed via filtration, and the obtained juice (extract) is collected; repeating the soaking or mixing steps as necessary, combining the obtained juices, and further concentrating, purifying or separating.

The term "preventing" as used herein refers to delaying the onset of symptoms or reducing the appearance of disease in a subject suffering from the disease.

The term "treating" as used herein means alleviating or ameliorating the symptoms of an affected individual.

The term "carrier" refers to diluents, excipients, acceptors or the like as are well known to those skilled in the art for preparing compositions.

When referring to ethanol concentration herein, it refers to the volume ratio (v/v) of ethanol to aqueous ethanol, e.g., 60% ethanol refers to 60ml of ethanol in 100ml of ethanol solution.

Unless otherwise required by the context, singular terms shall include the plural and plural terms shall include the singular.

The invention provides various forms of magnolia bark extracts and a preparation method thereof, wherein the magnolia bark extracts contain magnolia bark lignan C, magnolia bark lignan A, syringaresinol, cryptomeria japonica diol and taiwan xylol, but do not contain magnolol or honokiol. The magnolia bark extract of the present invention is prepared by the following steps: (a) extracting cortex Magnolia officinalis with water to obtain water extractive solution; and (b) introducing the water extract into a macroporous adsorption resin column, eluting with 30-60% ethanol, and collecting the eluate. Preferably, the ethanol of step (b) is 40-60% ethanol. More preferably, the ethanol of step (b) is 60% ethanol.

In a preferred embodiment, the Magnolia bark extract has a chemical fingerprint as shown in FIG. 1 as E or F.

The present invention also provides a composition comprising the magnolia bark extract of the present invention and an optionally acceptable carrier.

The invention also provides an application of the composition in preparing a medicine or health-care product for preventing or treating periodontal diseases, wherein the medicine or health-care product is in a form of mouthwash, toothpaste, oral patches, chewing gum or health-care food.

In a preferred embodiment, the composition reduces alveolar bone loss in patients with periodontal disease.

In a preferred embodiment, the pharmaceutical or nutraceutical is for administration of about 1 to 1000 milligrams of Magnolia bark extract of the present invention per kilogram of body weight. In a more preferred embodiment, the pharmaceutical or nutraceutical is for administration of about 25 to 200 milligrams of Magnolia bark extract of the present invention per kilogram of body weight. In a still more preferred embodiment, the pharmaceutical or nutraceutical is for administration of about 50 to 100 milligrams of Magnolia bark extract of the present invention per kilogram of body weight.

[ description of the drawings ]

FIG. 1 shows the chemical fingerprints of different Magnolia extracts, and HPLC (high performance liquid chromatography) spectrums A to G are respectively MO-W, MO-W-F1, MO-W-F2, MO-W-F3, MO-W-F4, MO-W-F5 and MO-W-F6.

FIG. 2 illustrates the separation process of different Magnolia bark extracts.

FIG. 3 is a computer tomography and alveolar bone height change measurements, DCB1 is ligature-induced + MO-W (100mpk, p.o.) group, DCB2 is ligature-induced + MO-W-F5(100mpk, p.o.) group, and DCB3 is ligature-induced + MO-W-F6(100mpk, p.o.) group.

FIG. 4 is a graph of computerized tomography showing the results of Magnolia bark active extract (MO-W-F5) comparing experimental versus clinical doxycycline administration in animals with ligation-induced periodontal disease.

FIG. 5 shows the results of HPLC analysis showing that the two major components of the active extract MO-W-F5, which are the most abundant, are concentrated in the separation fraction (9), while the other smaller components are concentrated in (8) and (10).

FIG. 6 shows the results of separation and identification of chemical components in the Magnolia bark active extract (MO-W-F5) using HPLC ultraviolet detector (UV wavelength of 254nm), wherein the detected index components are Magnolia bark lignan C, Magnolia bark lignan A, syringaresinol and Taiwan chaulmoogra phenol.

FIG. 7 shows the result of separation and identification of chemical components in Magnolia bark active extract (MO-W-F5) by HPLC high sensitivity laser counting detector (NQAD), wherein the detected indicator component is cryptomerin glycol.

[ detailed description ] embodiments

The invention may be embodied in different forms and is not limited to the embodiments set forth herein. The following examples are merely representative of various aspects and features of the present invention.

Example 1: materials and methods

Medicine and material

In the embodiment, the cortex magnoliae officinalis traditional Chinese medicinal material is dried bark, branch bark or root bark of magnolia officinalis or magnolia biloba belonging to Magnoliaceae, and is obtained by processing; macroporous adsorbent resins (Diaion HP20 resin) were purchased from Mitsubishi chemical Corporation; ethyl acetate, acetone and methanol were purchased from taiwan friend and trade ltd; 95% ethanol was purchased from Taiwan sugar industry Co., Ltd and from intensive medical science and technology Ltd; TLC plates were purchased from Merck nos. 1.05715 and 5554.

Apparatus and device

The reduced pressure concentrator used in the examples was Rotavapor RE111, the analyser was Thermo SpectraSYSTEM AS3000 and the column was Cosmosil5C18-MS-II,4.6 × 250 mm.

Extraction and separation method of magnolia officinalis

Taking the crushed magnolia officinalis, adding 10 times of deionized water (w: v =1:10(g/ml)), stirring, boiling and extracting for 1 hour, and performing air-suction filtration; stirring, boiling and extracting the filtered powder for 1 hour by 10 times of deionized water, and filtering by air suction; and combining the two filtrates, concentrating under reduced pressure to obtain an extract, and briefly referring the product to MO-W.

After the macroporous absorption resin is kept still for 12 hours by ethanol, the macroporous absorption resin is washed by deionized water to remove the ethanol, and a solvent with initial concentration is prepared to elute three times of the column volume, so that the column is completely maintained in the initial concentration state.

307.06g of Magnolia officinalis water extract (MO-W) was redissolved with 4 times of water (W: v =1:4(g/ml)), poured carefully into the upper layer of a macroporous adsorbent resin column (8L HP20) filled with water, adjusted to a flow rate of 0.5 column volumes per hour, and initially 1/5 column volumes were not collected. Then adjusting the flow rate to 1 column volume per hour, adjusting the flow rate to 2 column volumes per hour after collecting 1 column volume, eluting about five column volumes respectively by polarity gradient such as water, 10% ethanol, 20% ethanol, 40% ethanol, 60% ethanol and 95% ethanol, and the like, simultaneously confirming component difference by Thin Layer Chromatography (TLC), collecting eluent, concentrating, drying, and weighing to obtain different division parts. Wherein the product eluted by water is abbreviated as MO-W-F1, the product eluted by 10% ethanol is abbreviated as MO-W-F2, the product eluted by 20% ethanol is abbreviated as MO-W-F3, the product eluted by 40% ethanol is abbreviated as MO-W-F4, the product eluted by 60% ethanol is abbreviated as MO-W-F5 and the product eluted by 95% ethanol is abbreviated as MO-W-F6. FIG. 2 is a schematic diagram of the above process. The active ingredients of the magnolia bark lignan C, the magnolia bark lignan A, the syringaresinol, the cryptomeria japonica glycol, the Taiwan chaulmoogra phenol and the like are mainly concentrated in 30-60% ethanol eluent.

High Performance Liquid Chromatography (HPLC) analysis method for magnolia bark extract component

HPLC instrument, pump is SpectraSYSTEM P100, autosampler is SpectraSYSTEMAS1000, Detector is FINNIGAN SURVEYOR PDA Plus Detector, column is Cosmosil5C18-MS-II,4.6 × 250 mm.

Setting conditions of HPLC: sample concentration 10mg/mL in 50% MeOH/H₂O is in; the sample injection amount is 10 mu L; the flow rate is 1mL per minute; UV wavelength is 254 nm; the time program is shown in table one below:

watch 1

HPLC analysis patterns of different Magnolia extracts are shown in FIG. 1. Wherein A to G are HPLC spectra of MO-W, MO-W-F1, MO-W-F2, MO-W-F3, MO-W-F4, MO-W-F5 and MO-W-F6 in this order. Magnolol in fig. 1A accounts for about 0.060%; magnolol in fig. 1G is about 0.726%.

Example 2: small preparation of magnolia bark water extract

1Kg of magnolia officinalis medicinal material is added with 10L of 10 times of water and heated to boil for 1 hour, the mixture is filtered by a 100# screen, 10L of 10 times of water is added to the dregs of a decoction, the mixture is heated to boil for 1 hour, the mixture is filtered by the 100# screen, the liquid parts obtained by two-time sieving are combined, the mixture is centrifuged at 3000rpm for 15 minutes and then filtered by NO.1 filter paper, about 18L is obtained quantitatively, 116.84g of dry extract product can be obtained after concentration, and the yield is 11.7%.

Example 3: preparation of large amount of water extract of Magnolia officinalis

6Kg of magnolia officinalis medicinal material is extracted by 4 times, 10 times of water 60L is added into the medicinal material, the mixture is heated and boiled for 1 hour, the mixture passes through a 100# screen, 10 times of water 60L is added into the rest medicinal material, the mixture is heated and boiled for 1 hour, the mixture passes through the 100# screen, liquid parts obtained by two sieving processes are combined, the liquid parts are filtered through NO.1 filter paper, the volume of water extract is obtained quantitatively, the solid content is measured by sampling, the concentration is carried out to a proper volume, 628.12g of dry extract product can be obtained after the concentration, and the.

Example 4: ligature induced periodontal disease animal experiment

The experiments were carried out using male rats of the Sprague Dawley (SD) strain, which were approximately 280-310 g in weight. The ligature-induced periodontal disease method is described in 2008 by Cai et al (Cai X, Li C, Du G, CaoZ. protective effects of human on the tissue-induced periodontal disease. J. Periodont Res2008;43: 14-21).

Ligature-induced periodontal disease model (Ligature-induced periodontal disease model): rats were anesthetized by intraperitoneal injection, ligatures were placed on the neck of the first large molar tooth on both sides of the lower jaw and the neck of the second large molar tooth on the upper jaw, and ligatures were placed on the buccal-side proximal surface (day 0). Rats in the experimental group were given different magnolia bark extracts or drugs orally (p.o.) on days 3-10, respectively. Rats were sacrificed on day 11 and the alveolar bone height changes were visualized by tomography (Cheng W-C, Huang R-Y, Chiang C-Y, Chen J-K, Liu C-H, Chu C-L, FuE. around effect of dissipation on the depletion syndrome. J. Periodont Res2010;45: 788-.

Alveolar bone height measurement: after removing the remaining soft tissue from the lower jaw of the rat, the location of enamel-enamel junction (CEJ) was confirmed. The distance from the CEJ to the alveolar bone crest (CEJ-alveolarone crest) was measured by tomography, and the change in the alveolar bone height was observed.

Example 5: experimental results of Magnolia officinalis water extract (MO-W), active extract (MO-W-F5) and extract containing magnolol and honokiol (MO-W-F6) on animals with periodontal disease induced by ligation

This example is intended to demonstrate that the active extract of the present invention, which does not contain magnolol or honokiol, reduces alveolar bone destruction atrophy in ligature-induced periodontal disease in animal experiments. Animal experiments were performed in the manner described in example 4, with experimental animals randomized into five groups, with the following groups: 1) normal group (control group), 2) ligature-induced group, 3) ligature-induced + MO-W (100mpk) group (abbreviated DCB1), 4) ligature-induced + MO-W-F5(100mpk) group (abbreviated DCB2), 5) ligature-induced + MO-W-F6(100mpk) group (abbreviated DCB 3).

The computer tomograph (fig. 3) shows that in the group with ligature-induced periodontal disease, there was severe bone matrix resorption, either from the lingual or buccal side and compared to the normal group. MO-W-F5(100mg/kg) was administered to reduce alveolar bone destruction on both days 3 and 6. However, the magnolol and honokiol-containing extract group (MO-W-F6) had no significant effect on alveolar bone destruction.

Example 6: comparison result of cortex Magnolia officinalis active extract (MO-W-F5) on binding-induced periodontal disease animal experiment and clinical medication doxycycline

This example is intended to confirm the effect of different doses of Magnolia bark active extract (MO-W-F5) compared to clinically administered doxycycline in trials with ligature-induced periodontal disease animals.

Animal experiments were performed in the manner described in example 4, with the experimental animals randomized into five groups, with the following groups: 1) normal (control), 2) ligature-induced, 3) ligature-induced + doxycycline (100mpk), 4) ligature-induced + MO-W-F5(50mpk), 5) ligature-induced + MO-W-F5(100 mpk).

The computer tomograph (fig. 4) shows that there was severe bone matrix resorption in the group of ligature-induced periodontal diseases, both from lingual or buccal observation. Improved alveolar bone loss following administration of MO-W-F5(50mg/kg) was similar to doxycycline (100 mg/kg). MO-W-F5(100mg/kg) was administered to reduce alveolar bone destruction.

Example 7: HPLC analysis of Magnolia bark active extract (MO-W-F5)

Analyzing the components of the Magnolia officinalis active extract (MO-W-F5) with a high performance liquid chromatography under the following conditions:

watch two

The results show that the MO-W-F5 component does not contain magnolol and honokiol.

Example 8: separation and purification of active compounds in magnolia officinalis active extract (MO-W-F5) and structural identification

About 8.63g of magnolia bark active extract (MO-W-F5) is taken, 3 times the weight volume (about 25g) of silica gel is added to prepare dry powder, after separation by 120g of silica gel column (polarity gradient gradually changed from 100% ethyl acetate to 100% methanol within 60 minutes), 12 fractions are combined according to TLC, the polarity of the active isolate is about 40% -80% methanol/ethyl acetate. The results are shown in FIG. 5 by HPLC analysis, with the two major components of the active extract MO-W-F5, which are the most abundant, being concentrated in the separation section (9), and the other smaller components being concentrated in (8) and (10). Separating fractions (8), (9) and (10) with low polarity (EA, CH)₂Cl₂Or MeOH) or highly polar (MeOH and H)₂O) solvent mixing, separating and purifying by normal phase or reverse phase equal gradient open column to obtain five pure compounds (MO-1-MO-5). Taking a proper amount of pure compound to measure Mass Spectrum (MS),¹H NMR and¹³c NMR spectrum, presuming molecular formula, skeleton type and functional group, and comparing with literature, confirming the structure. The comparison results show that MO-1-MO-5 are Magnolia cortex lignan C, Magnolia cortex lignan A, syringaresinol, cryptomerin and Taiwan xylol, respectively, as shown in FIG. 6. Ultraviolet detector and laser counting detection (NQAD)The results of the HPLC analysis are shown in fig. 6 and 7.

Those skilled in the art will quickly appreciate that the present invention can be readily adapted to attain the ends and advantages mentioned, as well as those inherent therein. The extracts, compositions, processes and methods of making the same and uses thereof of the present invention are representative of preferred embodiments, which are exemplary and not limiting in scope. Modifications thereof and other uses will occur to those skilled in the art. Such modifications are intended to be included within the spirit of the present invention and defined in the following claims.

The description and examples are disclosed in detail to enable any person skilled in the art to make and use the invention, and they should be construed as without departing from the spirit and scope of the invention as defined by the appended claims.

All patents and publications mentioned in the specification are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element, or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the disclosure herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

Claims

1. A Magnolia bark extract for reducing alveolar bone loss in a periodontal patient, comprising Magnolia bark lignan C, Magnolia bark lignan A, syringaresinol, cryptomerin and Taiwan xylol, but not comprising magnolol and honokiol, wherein the Magnolia bark extract is prepared by the steps of: (a) extracting cortex Magnolia officinalis with water to obtain water extractive solution; and (b) introducing the water extract into a macroporous adsorption resin column, eluting with 60% ethanol, and collecting the eluate.

2. The magnolia extract of claim 1, having a chemical fingerprint as shown at F in fig. 1.

3. A method of preparing the magnolia extract of claim 1, comprising:

(a) extracting cortex Magnolia officinalis with water to obtain water extractive solution; and

(b) introducing the water extract into a macroporous adsorption resin column, eluting with 60% ethanol, and collecting eluate.

4. A composition comprising the magnolia bark extract of claim 1, and an optional carrier.

5. Use of the composition of claim 4 for the preparation of a medicament or health product for the prevention or treatment of periodontal disease.

6. The use of claim 5, wherein the composition reduces alveolar bone loss in periodontal patients.

7. The use as claimed in claim 5, wherein the pharmaceutical or nutraceutical is in the form of a mouthwash, toothpaste, oral patch, chewing gum or nutraceutical.